A Beacon for Gynecological Cancers Patients: pH-Sensitive Nanomedicine

Pramod Vishwanath Prasad and Anurag Srivastava

Center for Biomedical Research, Population Council, The Rockefeller University, USA Department of Surgical Disciplines, All India Institute of Medical Sciences, New Delhi, India

^*Correspondance to: Pramod Vishwanath Prasad 

 PDF  Full Text Review Article | Open Access

Abstract:

Emergence of various nanoscale drug carrier platforms as Drug Delivery Systems (DDS) has revolutionized the field of medicine. Nonetheless, the side-effects due to non-specific distribution of anticancer therapeutics in normal, healthy tissues remain to be a prime pitfall in curing cancers. Therefore,to achieve a better therapeutic efficacy the use of a target-specific delivery, combined with a stimuli-responsive nanocarrier system, particularly pH-sensitive nanosystems offer an attractive strategy. Targeted drug delivery through pH-sensitive nanosystems offer the potential to enhance the therapeutic index of anticancer agents either by increasing the drug concentration in tumor cells and/or by decreasing the exposure in normal host tissues. Therefore, nanoscale-based drug delivery through pH-sensitive nanosystems seem to be a boon for treating gynecological cancers (as well as other cancers) without side-effects or with least harm to normal health tissues

Keywords:

Cite the Article:

Prasad PV, Srivastava A. A Beacon for Gynecological Cancers Patients: pHSensitive Nanomedicine. Clin Oncol. 2020;5:1681.